Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

Cambrex Nears Completion of 5-year, $100-Million-Dollar Investment Plan, One Year Ahead of Schedule

EAST RUTHERFORD, N.J., March 18, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it is nearing the completion of a 5-year,$100-million-dollar investment strategy, one year ahead of schedule. The project, which adds mo...

2024-03-18 18:00 1526

Cambrex Nears Completion of 5-year, $100-Million-Dollar Investment Plan, One Year Ahead of Schedule

Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer

SHANGHAI, March 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, today announced that the company has strengthened i...

2024-03-18 09:00 1685

/C O R R E C T I O N -- Sisram Medical Ltd/

In the news release, Sisram Medical to Report FY2023 Financial Results on March 20 and Hold a Conference Call on March 21, issued on 14-Mar-2024 by Sisram Medical Ltd over PR Newswire, we are advised by the company that regarding the time, specifically, the Israel Time, should read "2:00 p.m." ra...

2024-03-15 16:42 2704

Novartis expands its biopharmaceutical manufacturing site in Singapore

* Invests US$256 million to expand biopharmaceutical manufacturing facility in Singapore, addressing the soaring demand in the Asian market * Set to generate 100 high skilled employment opportunities in Singapore's life science industry SINGAPORE, March 15, 2024 /PRNewswire/ -- Novartis today...

2024-03-15 14:55 3297

Qilu Pharmaceutical Showcases QL1706 Clinical Trial Outcomes in Oral Presentation at ESGO 2024

JINAN, China, March 15, 2024 /PRNewswire/ -- On 8 March local time, during the 25th European Society of Gynecological Oncology (ESGO) Conference (ESGO 2024) in Spain, Qilu Pharmaceutical unveiled the Phase II clinical trial results for iparomlimab and tuvonralimab (QL1706) in an oral presentation....

2024-03-15 14:07 2186

Seegene and Springer Nature Announce Awardees for the Open Innovation Program

* 26 submissions selected from a total of 281 applications from 47 countries to diagnose infectious and vector-borne diseases * Awardees representing 12 countries in Europe, the Americas, Asia and Africa , will receive research grants of up toUSD 600,000 per project * As part of the Seegene's...

2024-03-15 13:41 2180

Seegene and Springer Nature Announce Awardees for the Open Innovation Program

CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer

* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. * This marks the 13th NDA approval obtained by CStone and sugemalimab's fifth indication approved inChina, following stage III and IV no...

2024-03-15 12:10 2185

Alphamab Oncology to Present Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors at AACR 2024

SUZHOU, China, March 14, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that data from phase I clinical study conducted inAustralia (JSKN003-101) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, has b...

2024-03-14 08:39 1656

Hummingbird Bioscience and Dartmouth's Geisel School of Medicine to Co-Host 3rd Annual Virtual VISTA Symposium on March 27, 2024

SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience andDartmouth's Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually onWednesday, March 27, 2024 ( 11:00 AM - 3:30 PM ET). VISTA is a novel immune checkpoint imp...

2024-03-13 17:00 2280

Novel Molecules From Generative AI to Phase II: First Novel TNIK Inhibitors for Fibrotic Diseases Discovered and Designed Using Generative AI

* A study published in Nature Biotechnology presents the entire journey of INS018_055, from AI algorithms to Phase II clinical trials for the first time. * Raw data from 13 preclinical experiments and 3 clinical trials referenced in this study can be accessed by visiting Insilico'sdata room <...

2024-03-13 08:00 2185

Ajinomoto Bio-Pharma Services Garners Six 'CDMO Leadership Awards,' Further Establishing Its Industry Excellence

SAN DIEGO and TOKYO and WETTEREN, Belgium, March 12, 2024 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, received CDMO Leadership Awards in all six categories - Capabilities, Compatibility,...

2024-03-12 20:00 1771

Innovating the Future: ISoOR 2024 Annual Meeting Achieves Remarkable Success

SINGAPORE, March 12, 2024 /PRNewswire/ -- From March 7 to 8, 2024, the International Society of Organoid Research (ISoOR) convened its 2024 annual meeting, after the successful conference inSingapore last year. This year, the conference was held in the vibrant city ofShanghai, China, reflecting t...

2024-03-12 11:57 1628

Innovating the Future: ISoOR 2024 Annual Meeting Achieves Remarkable Success

SK Biopharmaceuticals Announces 100,000 Patients Globally Have Been Treated with Cenobamate Through Sales of XCOPRI® and ONTOZRY® in the U.S., Europe, Israel, and Canada

Milestone Coincides with SK Biopharmaceuticals' Global Plan Expanding Cenobamate Access to More Than 100 Markets Worldwide SEOUL, South Korea and ROME, March 12, 2024 /PRNewswire/ -- SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous system (CN...

2024-03-12 08:00 1460

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, March 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmu...

2024-03-12 08:00 1775

Appointment of Dr Darren Patti to Group Chief Operating Officer

MELBOURNE, Australia, March 12, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr.Darren Patti as Group Chief Operating Officer (COO), effective 11 March 2024. Dr. Patti joined Telix in March 2021 to lead the Company'...

2024-03-12 05:44 1470

ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results

SEOUL, South Korea, March 11, 2024 /PRNewswire/ -- ImmunAbs, a leading clinical-stage biotechnology company focused on developing novel antibody therapeutics, today announced the successful completion of the Phase 1 clinical trial for IM-101. IM-101 is a humanized monoclonal antibody targeting...

2024-03-11 17:00 1904

ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results

AI Empowers Surgery: CAIR unveils its latest large multimodality model for surgery

HONG KONG, March 11, 2024 /PRNewswire/ -- As artificial intelligence technology continues to advance, it has accelerated intelligent innovation across various industries. Breakthroughs in AI technologies like GPT have gained widespread attention, especially in the healthcare sector, where they of...

2024-03-11 15:06 1424

Apollo Hospitals Unveils South Asia's First ZAP-X, Transforming Brain Tumor Care

NEW DELHI, March 11, 2024 /PRNewswire/ -- Apollo Hospitals becomes the first hospital to introduce ZAP-X Gyroscopic Radiosurgery Platform, a significant milestone as the first inSouth Asia to introduce this ground-breaking technology. ZAP-X introduces a new era in brain tumor treatment, offering ...

2024-03-11 15:00 1546

Apollo Hospitals Unveils South Asia's First ZAP-X, Transforming Brain Tumor Care

RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024

YANTAI, China, March 11, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently gave an oral presentation on an interim analysis of the evaluation of the Company's proprietary Disitamab ...

2024-03-11 10:36 1368

Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau

-- Macau is on course to become the first of Everest's Asian territories to get etrasimod approval -- Can provide access to patients in China's Greater Bay area and rest of Asia SHANGHAI, March 11, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceu...

2024-03-11 09:00 2317

1 2 3 456 7 8 ... 181